The development of CpG island methylation biomarkers using restriction landmark genomic scanning

Annals of the New York Academy of Sciences

Volumn 983, Issue , 2003, Pages 110-119

  Smiraglia, Dominic J ^a   Plass, Christoph ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarkers; Cancer; DNA methylation; RLGS

Indexed keywords

BIOLOGICAL MARKER;

CANCER; CANCER DIAGNOSIS; CONFERENCE PAPER; CPG ISLAND; DNA METHYLATION; EARLY DIAGNOSIS; GENE DISRUPTION; GENE FREQUENCY; GENE TARGETING; HUMAN; RESTRICTION FRAGMENT;

EID: 0037354465     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb05966.x     Document Type: Conference Paper

References (45)

1. BESTOR, T.H. & TYCKO B. 1996. Creation of genomic methylation patterns. Nat. Genet. 12(4): 363-367.
2. BAYLIN, S.B., J.G. HERMAN, J.R. GRAFF, et al. 1998. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72: 141-196.
3. BIRD, A.P. 1986. CpG-rich islands and the function of DNA methylation. Nature 321(6067): 209-213.
4. ANTEQUERA, F. & A. BIRD. 1993. Number of CpG islands and genes in human and mouse. Proc. Natl. Acad. Sci. USA 90(24): 11995-11999.
5. GARDINER-GARDEN, M. & M. FROMMER. 1987. CpG islands in vertebrate genomes. J. Mol. Biol. 196(2): 261-282.
6. BAYLIN S.B., M. MAKOS., J.J. WU, et al. 1991. Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression. Cancer Cells 3(10): 383-390.
7. BAYLIN, S.B. 1997. Tying it all together: epigenetics, genetics, cell cycle, and cancer. Science 277(5334): 1948-1949.
8. JONES, P.A. 1996. DNA methylation errors and cancer. Cancer Res. 56(11): 2463-2467.
9. JONES P.A. & M.L. GONZALGO. 1997. Altered DNA methylation and genome instability: a new pathway to cancer? Proc. Natl. Acad. Sci. USA 94(6): 2103-2105.
10. LAIRD P.W. & R. JAENISCH. 1996. The role of DNA methylation in cancer genetic and epigenetics. Annu. Rev. Genet. 30: 441-464.
11. GAMA-SOSA M.A., V.A. SLAGEL, R.W. TREWYN, et al. 1983. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11(19): 6883-6894.
12. FRUHWALD, M.C., M.S. O'DORISIO, Z. DAI, et al. 2001. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - implications for tumor biology and potential clinical utility. Oncogene 20(36): 5033-5042.
13. COSTELLO, J.F., M.C. FRUHWALD, D.J. SMIRAGLIA, et al. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24(2): 132-138.
14. NAN, X., H.H. NG, C.A. JOHNSON, et al. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683): 386-389.
15. NG, H.H. & A. BIRD. 1999. DNA methylation and chromatin modification. Curr. Opin. Genet. Dev. 9(2): 158-163.
16. NAN, X., F.J. CAMPOY & A. BIRD. 1997. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88(4): 471-481.
17. BIRD, A.P. & A.P. WOLFFE. 1999. Methylation-induced repression: belts, braces, and chromatin. Cell 99(5): 451-454.
18. HERMAN, J.G., C.I. CIVIN, J.P. ISSA, et al. 1997. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 57(5): 837-841.
19. BELINSKY, S.A., K.J. NIKULA, W.A. PALMISANO, et al. 1998. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA 95(20): 11891-11896.
20. FUJIMOTO, J., W. YASUI, H. TAHARA, et al. 2000. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett. 149(1-2): 125-134.
21. ESTELLER, M., J. GARCIA-FONCILLAS, E. ANDION, et al. 2000. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343(19): 1350-1354.
22. MARUYAMA, R., S. TOYOOKA, K.O. TOYOOKA, et al. 2001. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 61(24): 8659-8663.
23. VIRMANI, A.K., J.A. Tsou, K.D. SIEGMUND, et al. 2002. Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol. Biomarkers Prev. 11(3): 291-297.
24. VOKES, E.E., R.R. WEICHSELBAUM, S.M. LIPPMAN, et al. 1993. Head and neck cancer. N. Engl. J. Med. 328(3): 184-194.
25. PANDE, P., M. MATHUR, N.K. SHUKLA, A, et al. 1999. Ets-1: a plausible marker of invasive potential and lymph node metastasis in human oral squamous cell carcinomas. J. Pathol. 189(1): 40-45.
26. HIRATSUKA, H., A. MIYAKAWA, K. NAKAMORI, et al. 1997. Multivariate analysis of occult lymph node metastasis as a prognostic indicator for patients with squamous cell carcinoma of the oral cavity. Cancer 80(3): 351-356.
27. WENNERBERG, J. 1996. Predicting response to therapy of squamous cell carcinoma of the head and neck (review). Anticancer Res. 16(4C): 2389-2396.
28. ZHANG, L., K.J. CHEUNG, JR., W.L. LAM, et al. 2001. Increased genetic damage in oral leukoplakia from high risk sites: potential impact on staging and clinical management. Cancer 91(11): 2148-2155.
29. SILVERMAN, S., JR., M. GORSKY & F. LOZADA. 1984. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 53(3): 563-568.
30. LEE, J.J., W.K. HONG, W.N. HITTELMAN, et al. 2000. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin. Cancer Res. 6(5): 1702-1710.
31. PAPADIMITRAKOPOULOU, V.A. 2000. Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal. Curr. Opin. Oncol. 12(3): 240-245.
32. PAPADIMITRAKOPOULOU, V. A. & W.K. HONG. 2000. Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer. Int. J. Cancer 88(6): 852-855.
33. HONG, W.K., S.M. LIPPMAN, L.M. ITRI, et al. 1990. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323(12): 795-801.
34. LIPPMAN, S.M., D.M. SHIN, J.J. LEE, et al. 1995. p53 and retinoid chemoprevention of oral carcinogenesis, Cancer Res. 55(1): 16-19.
35. ROSIN, M.P., X. CHENG, C. POH, et al. 2000. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin. Cancer Res. 6(2): 357-362.
36. SMIRAGLIA, D.J. & C. PLASS. 2002. The study of aberrant methylation in cancer via restriction landmark genomic scanning. Oncogene 21: 5414-5426.
37. OKAZAKI, Y., H. OKUIZUMI, N. SASAKI, et al. 1995. An expanded system of restriction landmark genomic scanning (RLGS Ver. 1.8). Electrophoresis 16(2): 197-202.
38. ESTELLER, M., P.G. CORN, S.B. BAYLIN, et al. 2001. A gene hypermethylation profile of human cancer. Cancer Res. 61(8): 3225-3229.
39. LIN, X., M. TASCILAR, W.H. LEE, et al. 2001. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 159(5): 1815-1826.
40. CALIFANO, J., P. VAN DER RIET, W. WESTRA, et al. 1996. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 56(11): 2488-2492.
41. REED, A.L., J. CALIFANO, P. CAIRNS, et al. 1996. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56(16): 3630-3633.
42. AKANUMA, D., N. UZAWA, M.A. YOSHIDA, et al. 1999. Inactivation patterns of the p16 (INK4a) gene in oral squamous cell carcinoma cell lines. Oral Oncol. 35(5): 476-483.
43. SMIRAGLIA, D.J., L.T. SMITH, J.C. LANG, et al. 2003. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J. Med. Genet..40: 25-33.
44. ROSAS, S.L., W. KOCH, M.G. DA COSTA CARVALHO; et al. 2001. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61(3): 939-942.
45. SANCHEZ-CESPEDES, M, M. ESTELLER, L. WU, et al. 2000. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60(4): 892-895.